| アブストラクト | OBJECTIVE: The purpose of this study was to evaluate the pharmacovigilance and clinical characteristics of psychiatric adverse events(AEs) related to Fluoroquinolones(FQs), and to determine the risk factors for timely management. METHODS: Data about AE reporting comes from the FDA Adverse Event Reporting System (FAERS) database, which was used for pharmacovigilance assessments. In addition, we also analyzed the cases of psychiatric AEs related to FQs retrospectively. RESULTS: Both of the FAERS database analysis and literature reports show that the proportion of FQs-related psychiatric AEs reported in females were higher (51.11% VS 33.44% and 53.23% VS 46.77%). Both of them show that the proportion of psychiatric AEs caused by FQs was higher in the age groups of 19-44 (28.08% and 40.32%) and 45-64 (28.17% and 25.81%). Most psychiatric AEs occurred within 10 days after FQs administration. Literature shows that 67.74% of the psychiatric AEs disappeared within 3 days after drug withdrawal (some cases were accompanied by other drug). CONCLUSION: Psychiatric AEs caused by FQs are serious, and there are many important safety signals that have not been mentioned in the label or previous studies. It is very important to identify and manage psychiatric AEs in time for the safe use of FQs. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2024/7/31 |
|---|
| 投稿者 | Li, JuanJuan; Yin, Xiaohong; Zhao, Yang; Yang, Xueqin; Wang, Jing; Yuan, Ting; Zheng, Juan; Tang, Qian; Wei, Wei |
|---|
| 組織名 | Department of Pharmacy, Guangyuan Central Hospital, Guanyuan, China.;Department of Pharmacy, Sichuan Mianyang 404 Hospital, Mianyang, China.;Department of Pharmacy, People's Hospital of Zhongjiang County, Deyang, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39082071/ |
|---|
